Safety & Side Effects

Real short-term signals, large long-term unknowns

CJC-1295 safety splits sharply by timeframe. In the short term the effects are real but the rates belong to one study each, so keep them labelled. The first Teichman study reported injection-site reactions in roughly 70% of treated subjects, headache in 63% against 14% on placebo, diarrhea in 43%, and systemic vasodilatory reactions (flushing, warmth and transient low blood pressure) in 30%. The second reported injection-site reactions in every treated subject, and Ionescu and Frohman reported a dose-dependent rise in heart rate. In the long term there is almost nothing, because no chronic human safety study exists.

This unit separates what is actually reported from what is mechanistically expected, and it takes the biggest theoretical concerns seriously without overclaiming: glucose handling, the acromegaly-shaped question of chronic excess, receptor desensitization, and the unresolved IGF-1 and cancer discussion that shadows the whole drug class.